RxDoctor Payments Data

Matthew Dorman, MD

Family Medicine · Palm Coast, FLNPI 1740284439

Payments from drug & device makers

$10,453in general payments, 2019–2025

Across 670 payments — averaging $15.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • GSK$1K
  • Lilly USA, LLC$560
  • Pfizer$533
  • AstraZeneca$500
  • plus $5K from 52 others

What the payments were for

  • Food & beverage$10,422100%
  • Education$310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)93$1,656
Novo Nordisk126$1,318
GSK76$1,019
Lilly USA, LLC37$560
Pfizer34$533
AstraZeneca34$500
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC21$335
Amarin Pharma, Inc.18$332
Sanofi-aventis U.S. LLC19$332
Abbott28$331
Otsuka America Pharmaceutical, Inc.14$284
Johnson & Johnson19$258
Astellas Pharma US Inc8$202
Boehringer Ingelheim12$195
Amgen(2 entities)10$183
Lundbeck LLC6$180
Sumitomo Pharma America, Inc.9$178
Sebela Pharmaceuticals Inc.1$175
Exact Sciences7$151
Merck7$129
Novartis9$127
Sunovion Pharmaceuticals Inc.8$118
Idorsia Pharmaceuticals US Inc4$114
Esperion Therapeutics, Inc.7$113
Corcept Therapeutics6$96
Mylan Specialty L.p.4$89
Daiichi Sankyo Inc.5$79
Bayer5$75
Inspire Medical Systems, Inc.2$68
Alk-abello, Inc3$66
Incyte Corporation2$47
Xeris Pharmaceuticals, Inc.2$45
Hikma Pharmaceuticals USA3$45
Eisai Inc.2$42
Kowa Pharmaceuticals America, Inc.3$40
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$36
Shield Therapeutics Inc1$32
Dexcom, Inc.1$32
ARS Pharmaceuticals Operations, Inc.2$31
Axonics, Inc.2$23
IBSA Pharma Inc.1$20
Seqirus USA Inc1$19
Melinta Therapeutics, LLC1$19
Nabriva Therapeutics, PLC1$18
Tolmar, Inc.1$17
Jazz Pharmaceuticals Inc.1$17
Medtronic1$17
Biogen1$16
Axsome Therapeutics, Inc.1$15
Teva Pharmaceuticals USA, Inc.1$15
CMP Pharma, Inc.1$15
Eyevance Pharmaceuticals LLC1$14
Biohaven Pharmaceutical Holding Company Ltd.1$14
Ascensia Diabetes Care US Inc.1$14
Biohaven Pharmaceuticals, Inc.1$14
Lucid Diagnostics Inc.1$14
Nestle Healthcare Nutrition Inc.1$13
Amneal Pharmaceuticals LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,453 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$363,312
Medicare patients
693
Services billed
10,252

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide229$378,713
EliquisApixaban165$193,457
Xeljanz XrTofacitinib Citrate28$183,693
MounjaroTirzepatide93$115,743
Humira PenAdalimumab14$112,811
XareltoRivaroxaban95$110,204
Trelegy ElliptaFluticasone/Umeclidin/Vilanter64$86,319
JardianceEmpagliflozin57$82,048
MyrbetriqMirabegron72$80,598
RexultiBrexpiprazole39$61,520
UbrelvyUbrogepant28$59,709
JanuviaSitagliptin Phosphate40$57,752
FarxigaDapagliflozin Propanediol43$54,663
RybelsusSemaglutide25$42,673
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$29,906

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,318$421,386254 claims
PfizerEliquis, Nurtec Odt$533$217,325176 claims
Lilly USA, LLCMounjaro, Trulicity$560$144,254104 claims
AbbVieUbrelvy, Vraylar, Linzess, Creon$1,656$123,39082 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,019$112,19095 claims
Johnson & JohnsonXarelto$258$110,20495 claims
Boehringer IngelheimJardiance, Glyxambi$195$101,10674 claims
AstraZenecaFarxiga, Breztri Aerosphere$500$84,56959 claims
Astellas Pharma US IncMyrbetriq$202$80,59872 claims
MerckJanuvia, Belsomra$129$70,60258 claims
Otsuka America Pharmaceutical, Inc.Rexulti$284$61,52039 claims
NovartisEntresto$127$29,06322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Palm Coast

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →